https://www.scmp.com/rss/56733/feed The London-based multinational drugmaker, also known as GSK, supplies key products such as vaccines in China, as well as drugs for lung disease and cancer. In 2013, the company was targeted by Chinese authorities over alleged corruption, price-fixing and quality controls. en https://assets.i-scmp.com/static/img/icons/scmp-meta-1200x630.png https://www.scmp.com Connor Mycroft Connor Mycroft Twenty-two strategic enterprises have signed agreements with the Office for Attracting Strategic Enterprises (OASES) to open or expand operations in Hong Kong. The latest group marks the sixth cohort under the government’s flagship investment attraction initiative since its launch in 2022, bringing the total number of strategic partners to more than 120. The South China Morning Post looks at who the latest companies are and the anticipated economic impact. 1. Who are the corporations? Pfizer, a... https://www.scmp.com/news/hong-kong/hong-kong-economy/article/3350780/which-global-firms-are-being-attracted-hong-kongs-strategic-enterprise-scheme?utm_source=rss_feed https://www.scmp.com/news/hong-kong/hong-kong-economy/article/3350780/which-global-firms-are-being-attracted-hong-kongs-strategic-enterprise-scheme?utm_source=rss_feed Tue, 21 Apr 2026 01:30:31 +0000 Luna Sun Luna Sun AstraZeneca’s former China head has been formally charged with medical insurance fraud, illegal trading and unlawful collection of personal information, more than a year after he first came under investigation – casting a shadow over the Swedish-British drug maker’s expansion in its second-largest market. The pharmaceutical giant confirmed to the Financial Times and Reuters that Leon Wang was one of two individuals indicted, as referenced in its latest earnings report published on Tuesday. The... https://www.scmp.com/economy/china-economy/article/3343522/china-charges-former-astrazeneca-executive-what-it-means-global-pharmaceutical-firms?utm_source=rss_feed https://www.scmp.com/economy/china-economy/article/3343522/china-charges-former-astrazeneca-executive-what-it-means-global-pharmaceutical-firms?utm_source=rss_feed Fri, 13 Feb 2026 12:00:12 +0000 Julie Zhang Julie Zhang Chinese drug makers’ licensing deals more than doubled in 2025 from a year earlier to a record high, propelled by dozens of multibillion-dollar agreements between Hong Kong and mainland China-listed firms and global pharmaceutical giants. Last year, 157 out-licensing deals worth US$135.7 billion were signed, compared with 94 transactions worth US$51.9 billion in 2024, state media reported, citing data released by the National Medical Products Administration (NMPA), China’s drugs regulator, last... https://www.scmp.com/business/china-business/article/3339011/chinese-drug-makers-strike-record-us136-billion-out-licensing-deals-2025?utm_source=rss_feed https://www.scmp.com/business/china-business/article/3339011/chinese-drug-makers-strike-record-us136-billion-out-licensing-deals-2025?utm_source=rss_feed Thu, 08 Jan 2026 00:30:09 +0000 Kamala Thiagarajan Kamala Thiagarajan China’s pharmaceutical industry is on the brink of enormous growth and transformation. In just a few years, it has moved on from being the world’s cheapest source of active pharmaceutical ingredients to becoming a major hub for pharmaceutical innovation – a place where new, more effective drugs are born. It is now the second-largest developer of drugs, trailing only the United States. In the global drug development pipeline, China’s growth rate is phenomenal, leaping from 3 per cent in 2013 to... https://www.scmp.com/opinion/china-opinion/article/3334948/how-china-went-generic-drug-factory-biomedicine-innovator?utm_source=rss_feed https://www.scmp.com/opinion/china-opinion/article/3334948/how-china-went-generic-drug-factory-biomedicine-innovator?utm_source=rss_feed Thu, 04 Dec 2025 01:30:09 +0000 Letters Letters Feel strongly about these letters, or any other aspects of the news? Share your views by emailing us your Letter to the Editor at letters@scmp.com or filling in this Google form. Submissions should not exceed 400 words On October 9, the Office for Attracting Strategic Enterprises welcomed a new batch of strategic enterprises establishing or expanding their operations in Hong Kong, including top global pharmaceutical companies such as GlaxoSmithKline and Roche. They aim to expand their innovative... https://www.scmp.com/opinion/letters/article/3330170/how-hong-kong-can-help-chinese-drug-makers-go-global?utm_source=rss_feed https://www.scmp.com/opinion/letters/article/3330170/how-hong-kong-can-help-chinese-drug-makers-go-global?utm_source=rss_feed Mon, 27 Oct 2025 03:30:08 +0000 Emily Hung Emily Hung A US-based Emmy Award-winning digital content protection firm is among the latest batch of strategic enterprises that will open offices or expand in Hong Kong, seeking to leverage the city’s creative talent and accelerate its intellectual property (IP) development. Financial Secretary Paul Chan Mo-po said the Office for Attracting Strategic Enterprises (OASES) had brought in 18 more firms to establish offices or expand in the city. With their addition, the total number of OASES enterprises would... https://www.scmp.com/news/hong-kong/hong-kong-economy/article/3328405/digital-ip-protector-us-among-18-firms-expanding-hong-kong?utm_source=rss_feed https://www.scmp.com/news/hong-kong/hong-kong-economy/article/3328405/digital-ip-protector-us-among-18-firms-expanding-hong-kong?utm_source=rss_feed Thu, 09 Oct 2025 11:40:55 +0000 Elizabeth Cheung Elizabeth Cheung A Hong Kong government-owned clinical trial institute will launch a study to examine the long-term health effects of the shingles vaccine in real-world settings, collaborating with a global pharmaceutical giant and a local university. The Greater Bay Area International Clinical Trial Institute, together with the University of Hong Kong’s medical school and GlaxoSmithKline (GSK), signed a memorandum of understanding on Tuesday to mark their collaboration on the project. Professor Ian Wong... https://www.scmp.com/news/hong-kong/health-environment/article/3324902/hong-kong-launch-collaborative-study-long-term-effects-shingles-vaccine?utm_source=rss_feed https://www.scmp.com/news/hong-kong/health-environment/article/3324902/hong-kong-launch-collaborative-study-long-term-effects-shingles-vaccine?utm_source=rss_feed Tue, 09 Sep 2025 09:35:18 +0000 Julie Zhang Julie Zhang Jiangsu Hengrui Pharmaceuticals, a Chinese developer of novel drugs, could receive up to US$1.01 billion in milestone payments after granting a US company exclusive rights to develop a heart disease drug, the latest example of mainland drug makers licensing early-stage assets to international partners. Jiangsu Hengrui entered into a licensing agreement with one-year-old US start-up Braveheart Bio for its innovative drug HRS-1893 to treat obstructive hypertrophic cardiomyopathy, according to a... https://www.scmp.com/business/china-business/article/3324435/chinas-jiangsu-hengrui-signs-licensing-deal-braveheart-bio-heart-drug?utm_source=rss_feed https://www.scmp.com/business/china-business/article/3324435/chinas-jiangsu-hengrui-signs-licensing-deal-braveheart-bio-heart-drug?utm_source=rss_feed Fri, 05 Sep 2025 04:54:34 +0000 Eric Ng Eric Ng Jiangsu Hengrui Pharmaceuticals and Hansoh Pharmaceutical Group, two of China’s largest drug makers, are expected to report significantly improved profits, buoyed by novel drug roll-outs and revenue from technology licensing. On August 21, Hengrui, China’s largest drug maker by market value, is expected to say its net profit for the first half rose 40 per cent from a year earlier to 4.1 billion yuan (US$570.8 million), with revenue up 9 per cent to 15.7 billion yuan, according to analysts’... https://www.scmp.com/business/article/3322005/chinese-pharma-firms-hengrui-hansoh-expected-post-strong-first-half-profits?utm_source=rss_feed https://www.scmp.com/business/article/3322005/chinese-pharma-firms-hengrui-hansoh-expected-post-strong-first-half-profits?utm_source=rss_feed Sun, 17 Aug 2025 23:30:12 +0000 David Chao David Chao As Greater China markets charge into the third quarter with the wind at their backs, there is increasing evidence that 2025 is the year Chinese intellectual property goes global. A month ago, I wrote about the peculiar appeal of the Labubu doll, which seemingly leapt out of nowhere to become a global pop culture phenomenon. This was the latest example of a successful Chinese entertainment IP – a unique asset with intangible social value – taking off. Meanwhile, China is also making huge progress... https://www.scmp.com/opinion/china-opinion/article/3320580/biotech-successes-helping-chinese-intellectual-property-go-global?utm_source=rss_feed https://www.scmp.com/opinion/china-opinion/article/3320580/biotech-successes-helping-chinese-intellectual-property-go-global?utm_source=rss_feed Mon, 04 Aug 2025 21:30:08 +0000 Eric Ng Eric Ng GlaxoSmithKline (GSK) will potentially pay a Chinese company US$12.5 billion for exclusive global rights to develop a dozen drugs, in a landmark deal that underscores how China’s research labs are snapping up market share in the global pharmaceutical and biomedical industries. The deal would give GSK the rights to develop a drug for treating chronic obstructive pulmonary disease (COPD) called HRS-9821, as well as 11 of the preclinical programmes owned by Jiangsu Hengrui Pharmaceuticals. The... https://www.scmp.com/business/article/3319793/gsk-signs-us125-bn-licence-deal-hengrui-china-rises-global-pharmaceuticals?utm_source=rss_feed https://www.scmp.com/business/article/3319793/gsk-signs-us125-bn-licence-deal-hengrui-china-rises-global-pharmaceuticals?utm_source=rss_feed Mon, 28 Jul 2025 04:19:45 +0000 Resty Woro Yuniar Resty Woro Yuniar Indonesia’s role in a high-profile tuberculosis (TB) vaccine trial funded by the Bill & Melinda Gates Foundation has unleashed a wave of conspiracy theories and misinformation online – prompting health officials to clarify that the country was not being treated as a “guinea pig” and that the jab was not developed by Gates himself. The backlash began after President Prabowo Subianto met Microsoft co-founder and philanthropist Bill Gates at the presidential palace in Jakarta on May 7. Following... https://www.scmp.com/week-asia/health-environment/article/3310502/indonesia-defends-tb-vaccine-trial-bill-gates-conspiracy-theories-spread-not-guinea-pigs?utm_source=rss_feed https://www.scmp.com/week-asia/health-environment/article/3310502/indonesia-defends-tb-vaccine-trial-bill-gates-conspiracy-theories-spread-not-guinea-pigs?utm_source=rss_feed Thu, 15 May 2025 10:07:09 +0000 The US Food and Drug Administration (FDA) approved British drug maker GSK’s combination vaccine to protect against meningococcal infection for use in people aged 10 through 25 years, the company said on Saturday. Meningococcal infections, caused by bacteria called Neisseria meningitidis, can lead to severe, sometimes deadly, bloodstream infections as well as severe swelling in the brain and spinal cord. The vaccine, called Penmenvy, combines the immune response-generating components of two of... https://www.scmp.com/news/world/united-states-canada/article/3298850/fda-approves-gsk-vaccine-combat-meningococcal-infections?utm_source=rss_feed https://www.scmp.com/news/world/united-states-canada/article/3298850/fda-approves-gsk-vaccine-combat-meningococcal-infections?utm_source=rss_feed Sat, 15 Feb 2025 13:42:01 +0000 The World Health Organization (WHO) recommended on Monday the use of a second malaria vaccine to curb the life-threatening disease spread to humans by some mosquitoes. “Almost exactly two years ago, WHO recommended the broad use of the world’s first malaria vaccine called ‘RTS, S,’” WHO director general Tedros Adhanom Ghebreyesus told a briefing in Geneva. “Today, it gives me great pleasure to announce that WHO is recommending a second vaccine called R21/Matrix-M to prevent malaria in children... https://www.scmp.com/news/world/europe/article/3236565/who-recommends-malaria-vaccine-children-be-rolled-out-next-year?utm_source=rss_feed https://www.scmp.com/news/world/europe/article/3236565/who-recommends-malaria-vaccine-children-be-rolled-out-next-year?utm_source=rss_feed Mon, 02 Oct 2023 17:09:43 +0000 Half a Greek alphabet and two years into the pandemic, the world is coming to terms with the notion that Covid-19 is here to stay. As new variants emerge, millions are still falling ill, increasing the risk of even harder-hitting strains. While coronavirus vaccines are among the greatest medical achievements of all time, reaching the market in less than a year and saving millions of lives, anyone who has received three doses and still got infected will understand that the virus is a resilient... https://www.scmp.com/magazines/post-magazine/long-reads/article/3180098/future-covid-19-vaccines-why-nasal-sprays-not?utm_source=rss_feed https://www.scmp.com/magazines/post-magazine/long-reads/article/3180098/future-covid-19-vaccines-why-nasal-sprays-not?utm_source=rss_feed Fri, 03 Jun 2022 20:15:11 +0000 GlaxoSmithKline has agreed to help manufacture as many as 60 million UK doses of a Covid-19 vaccine from Novavax as the British government looks to shore up supplies amid tensions with the European Union. The British pharmaceutical company will provide the fill-finish capacity – putting the vaccine into vials and packaging – for the Novavax shot at its Barnard Castle site in Durham, England, Glaxo said in a statement on Monday. Novavax is expected to apply for UK approval of its vaccine in the... https://www.scmp.com/news/world/europe/article/3127595/glaxosmithkline-manufacture-novavax-covid-19-vaccine-uk-securing?utm_source=rss_feed https://www.scmp.com/news/world/europe/article/3127595/glaxosmithkline-manufacture-novavax-covid-19-vaccine-uk-securing?utm_source=rss_feed Tue, 30 Mar 2021 06:00:23 +0000 Shanghai-based Genor Biopharma, which made a successful debut on Hong Kong stock exchange on Wednesday, is looking to offer cheaper treatments for breast cancer – the most common among all cancers in Chinese women. “We aim to be a leading breast cancer therapies provider among domestic firms in three to five years,” chief executive officer Guo Feng told the Post. “We are building a sales team for multiple drug candidates in this category, and our superior manufacturing capabilities mean we can a... https://www.scmp.com/business/companies/article/3104481/genor-biopharma-eyes-top-position-among-chinese-firms-breast?utm_source=rss_feed https://www.scmp.com/business/companies/article/3104481/genor-biopharma-eyes-top-position-among-chinese-firms-breast?utm_source=rss_feed Wed, 07 Oct 2020 05:30:12 +0000 Stada Arzneimittel, a German drug maker owned by private equity firms Bain Capital and Cinven, is turning to China to strengthen its global supply security while enhancing its presence in Asia’s biggest pharmaceutical market. The company is seeking partnerships to source more raw materials from the mainland as an insurance, an official said. Disruptions caused by the coronavirus pandemic since January have raised awareness among global drug manufacturers on the importance of health care supply... https://www.scmp.com/business/companies/article/3087367/pandemic-lesson-german-drug-maker-stada-banks-china-raw?utm_source=rss_feed https://www.scmp.com/business/companies/article/3087367/pandemic-lesson-german-drug-maker-stada-banks-china-raw?utm_source=rss_feed Wed, 03 Jun 2020 08:45:09 +0000 Britain’s broadcasting watchdog has launched a formal investigation into whether a confession made by a British man and aired on China’s state broadcaster broke UK broadcasting rules when shown there. The investigation relates to a complaint made by Briton Peter Humphrey and his American wife, Yu Yingzeng, who were both sentenced in China in 2014 for illegally obtaining private records of Chinese citizens and selling the information to clients including drug maker GlaxoSmithKline. Humphrey... https://www.scmp.com/news/china/article/3009443/british-watchdog-ofcom-investigates-china-central-television-airing?utm_source=rss_feed https://www.scmp.com/news/china/article/3009443/british-watchdog-ofcom-investigates-china-central-television-airing?utm_source=rss_feed Wed, 08 May 2019 18:38:47 +0000 Malawi on Tuesday rolled out the world’s first licensed malaria vaccine in a landmark campaign against a disease that each year kills hundreds of thousands of people, especially African children. After more than three decades in development and almost US$1 billion in investment, the new vaccine began to be distributed in Malawi’s capital Lilongwe. It will be extended to Kenya and Ghana in coming weeks. “We have seen tremendous gains from bed nets and other measures to control malaria in the... https://www.scmp.com/news/world/africa/article/3007401/malawi-becomes-worlds-first-country-roll-out-ground-breaking?utm_source=rss_feed https://www.scmp.com/news/world/africa/article/3007401/malawi-becomes-worlds-first-country-roll-out-ground-breaking?utm_source=rss_feed Tue, 23 Apr 2019 22:39:35 +0000 The US Securities and Exchange Commission’s recently released 2017 whistle-blower report shows a 72 per cent increase in informants coming from mainland China and Hong Kong. In 2016, a total of 36 people who filed reward submissions under the Dodd-Frank Act were from the mainland and Hong Kong, compared with 62 this year. Our law group, a Dodd-Frank whistle-blower firm, has witnessed the surge in whistle-blower clients from China as a result of Beijing’s anti-corruption efforts and the US... https://www.scmp.com/comment/insight-opinion/article/2121681/how-china-and-us-are-emboldening-whistle-blowers-fight?utm_source=rss_feed https://www.scmp.com/comment/insight-opinion/article/2121681/how-china-and-us-are-emboldening-whistle-blowers-fight?utm_source=rss_feed Mon, 27 Nov 2017 04:38:54 +0000 By Lydia Ramsey The FDA approved a two-drug regimen for HIV for the first time on Tuesday. The pill, which contains dolutegravir with rilpivirine, is made by ViiV, the specialist HIV company majority owned by GlaxoSmithKline, that has Pfizer and Japanese pharmaceutical company Shionogi as shareholders. Up until now, people living with HIV suppress the virus with a regimen of three or four pills. Keeping the amount of HIV in the blood low is key for suppressing symptoms of the virus. And the hope... https://www.scmp.com/tech/science-research/article/2121056/new-drug-treat-hiv-just-got-approved-us-and-it-could-shake?utm_source=rss_feed https://www.scmp.com/tech/science-research/article/2121056/new-drug-treat-hiv-just-got-approved-us-and-it-could-shake?utm_source=rss_feed Wed, 22 Nov 2017 07:00:00 +0000 Chinese e-commerce giant Alibaba is pushing for one more inclusion in this year’s Singles’ Day shopping trolley – HPV vaccine. GlaxoSmithKline’s Cervarix is the first HPV vaccine licensed by the China Food and Drug Administration, and is targeted at girls and women of ages between nine and 25 years. A tie-up between pharmaceutical giant GSK and Alibaba Health will let users access online consultation services and book appointments for the anti-cervical cancer drug in more than 100 cities in... https://www.scmp.com/tech/enterprises/article/2119348/alibaba-ties-glaxosmithkline-online-hpv-vaccine-appointment-service?utm_source=rss_feed https://www.scmp.com/tech/enterprises/article/2119348/alibaba-ties-glaxosmithkline-online-hpv-vaccine-appointment-service?utm_source=rss_feed Fri, 10 Nov 2017 09:43:46 +0000 A judge in the United States has dismissed a lawsuit by two former corporate investigators who accused British pharmaceutical company GlaxoSmithKline of misleading them into investigating a whistle-blower in China, leading to their arrest amid a bribery scandal involving the drug maker. US District Judge Nitza Quinones Alejandro in Philadelphia on Friday threw out the case by British investigator Peter Humphrey and his American wife, Yu Yingzeng, who were arrested in 2013 in China after GSK... https://www.scmp.com/news/china/policies-politics/article/2113790/us-judge-dismisses-ex-sleuths-lawsuit-against?utm_source=rss_feed https://www.scmp.com/news/china/policies-politics/article/2113790/us-judge-dismisses-ex-sleuths-lawsuit-against?utm_source=rss_feed Tue, 03 Oct 2017 05:11:19 +0000 Last month, a court in Lanzhou city jailed and fined six Nestlé employees, after a years-long investigation into bribery allegations surrounding sales of baby formula. In 2013, Reuters found that Nestlé’s staff regularly bribed hospital staff in China to exclusively supply its milk formula to newborns. That practice ran afoul of a 1995 law that bars health practitioners from promoting formula over breastfeeding. It also contravened global guidelines of the World Health Organisation. Other... https://www.scmp.com/comment/insight-opinion/article/2107769/china-has-message-western-companies-corruption-does-not-pay?utm_source=rss_feed https://www.scmp.com/comment/insight-opinion/article/2107769/china-has-message-western-companies-corruption-does-not-pay?utm_source=rss_feed Tue, 22 Aug 2017 06:55:17 +0000 Verily (formerly Google Life Sciences)  has its hands in a lot of projects.  The life sciences company has been developing glucose-monitoring contact lenses, and it makes silverware that makes it easier for people with hand tremors to eat. Along the way, Verily has partnered with some of the biggest names in pharma in everything from diabetes care to a surgical robot spin-out company.  Its latest endeavor? A joint venture with British pharmaceutical company GlaxoSmithKline, called Galvani... https://www.scmp.com/tech/innovation/article/1998932/new-joint-venture-study-electronic-implants-treat-conditions?utm_source=rss_feed https://www.scmp.com/tech/innovation/article/1998932/new-joint-venture-study-electronic-implants-treat-conditions?utm_source=rss_feed Wed, 03 Aug 2016 20:15:15 +0000 At a closed-door trial held last month in Hunan province, one-time high-flying business executive Mark Reilly was handed a three-year suspended prison sentence for his role in the largest corporate bribery scandal involving a foreign firm in China. As the former country manager of British pharmaceutical maker GlaxoSmithKline, Reilly was due to be expelled from China and his company slapped with a US$489 million fine, according to Xinhua. However, Reilly's return to Britain might not mean the end... https://www.scmp.com/business/companies/article/1641600/nowhere-hide-bribery-laws?utm_source=rss_feed https://www.scmp.com/business/companies/article/1641600/nowhere-hide-bribery-laws?utm_source=rss_feed Sun, 16 Nov 2014 21:15:00 +0000 When Cathy Palmer first came to Hong Kong as a US prosecutor more than 20 years ago, she was chasing heroin-smuggling triads who later sent a booby-trapped package to her Brooklyn office. Since March, she has been in the city, "talking to people about tough things" to help clients of Latham & Watkins deal with mushrooming investigations into potential crimes and corporate misconduct. Palmer's US law firm is not alone in boosting its presence in the city, home to the Asia headquarters of Wall... https://www.scmp.com/business/economy/article/1626305/hong-kong-hot-spot-lawyers?utm_source=rss_feed https://www.scmp.com/business/economy/article/1626305/hong-kong-hot-spot-lawyers?utm_source=rss_feed Mon, 27 Oct 2014 21:42:51 +0000 In the wake of the Chinese government's punishment of GlaxoSmithKline (GSK) and some of its former senior executives for corruption, multinationals are changing their behaviour and strategies in China, said industry observers. Last Friday, Chinese state media reported that a 3 billion yuan (HK$3.8 billion) fine had been slapped on Britain's biggest drug firm, the largest corporate fine ever imposed by Beijing, as well as jail sentences of two to three years for former senior China executives of... https://www.scmp.com/business/china-business/article/1598359/multinationals-china-alert-wake-gsk-case?utm_source=rss_feed https://www.scmp.com/business/china-business/article/1598359/multinationals-china-alert-wake-gsk-case?utm_source=rss_feed Mon, 22 Sep 2014 21:18:18 +0000 China's e-commerce leader, Alibaba, celebrated its landmark US$21.8 billion listing in New York on Friday - the largest IPO in American history - on the same day that British pharmaceuticals giant GlaxoSmithKline was hit by a record fine of US$500 million imposed by the central government. The two stories - one happy and the other unfortunate - are perfect examples to showcase the rise of China on both the economic and political fronts on the world stage. Alibaba puts China on par with the... https://www.scmp.com/business/china-business/article/1597542/tale-alibaba-and-gsk-sign-chinas-rise-world-stage?utm_source=rss_feed https://www.scmp.com/business/china-business/article/1597542/tale-alibaba-and-gsk-sign-chinas-rise-world-stage?utm_source=rss_feed Sun, 21 Sep 2014 20:30:15 +0000 China has imposed a record fine of three billion yuan (HK$3.78 billion) on British pharmaceuticals giant GlaxoSmithKline (GSK) for bribing doctors to use its drugs. Mark Reilly, the former head of GSK in China, was sentenced to three years in jail suspended for four years. He would be expelled from China, Xinhua reported. Four other GSK executives - all Chinese - were given suspended jail sentences ranging from two to three years. Changsha Intermediate People's Court in Hunan province ruled GSK... https://www.scmp.com/news/china/article/1596109/glaxosmithkline-hit-record-3b-yuan-fine-bribing-chinese-doctors?utm_source=rss_feed https://www.scmp.com/news/china/article/1596109/glaxosmithkline-hit-record-3b-yuan-fine-bribing-chinese-doctors?utm_source=rss_feed Fri, 19 Sep 2014 08:45:45 +0000 A US anti-bribery probe into GlaxoSmithKline touched on the firm's Chinese consumer health care business in 2012, internal documents show, suggesting the drugmaker's compliance problems in China could go wider than previously revealed. GSK confirmed it had conducted an investigation into procurement practices in consumer health care in China, but said it did not find any "unethical conduct". It said the inquiry was unrelated to a Chinese criminal investigation into corruption in its... https://www.scmp.com/business/companies/article/1588906/glaxosmithkline-china-health-care-unit-part-us-probe?utm_source=rss_feed https://www.scmp.com/business/companies/article/1588906/glaxosmithkline-china-health-care-unit-part-us-probe?utm_source=rss_feed Tue, 09 Sep 2014 20:00:00 +0000 A year after their detention sent shockwaves through China's booming due-diligence industry, British corporate investigator Peter Humphrey was sentenced last night to two-and-a-half years in prison and his wife, Yu Yingzeng, to two years. The Shanghai No 1 Intermediate People's Court also fined Humphrey 200,000 yuan (HK$250,000) and Yu 150,000 yuan for illegally obtaining private information on Chinese citizens after the one-day trial. Humphrey will be deported after serving his jail term. After... https://www.scmp.com/news/china/article/1569614/investigator-peter-humphrey-and-wife-jailed-buying-private-information?utm_source=rss_feed https://www.scmp.com/news/china/article/1569614/investigator-peter-humphrey-and-wife-jailed-buying-private-information?utm_source=rss_feed Fri, 08 Aug 2014 15:30:45 +0000 11.20pm: The couple's son, Harvey, 19, said "They were allowed to speak and present defence. I'm very sad about the court's verdict but I hope the authorities would take into account of their poor health. I'm absolutely exhausted. I'm going home tonight." 11.07pm: The couple have five days to appeal this verdict. Court is adjourned. 11.05pm: The court sentences Yu to two years and in prison on charges of "illegally obtaining private information", and a fine of 150,000 yuan.  11.00pm: The court... https://www.scmp.com/news/china/article/1568950/live-gsk-private-investigator-peter-humphrey-wife-stand-trial-privacy?utm_source=rss_feed https://www.scmp.com/news/china/article/1568950/live-gsk-private-investigator-peter-humphrey-wife-stand-trial-privacy?utm_source=rss_feed Fri, 08 Aug 2014 01:30:00 +0000 Peter Humphrey was caught, literally, by the increasing restrictions on obtaining information on the mainland. The Briton and his American wife, Yu Yingzeng, will be tried this morning at the Shanghai No 1 Intermediate People's Court for illegally obtaining personal information of Chinese citizens. In April last year, Humphrey was hired by senior executives of GlaxoSmithKline (GSK), Britain's largest drug firm, to investigate a suspected whistle-blower who alleged bribery in GSK's China... https://www.scmp.com/news/china/article/1568674/gsk-sleuth-peter-humphrey-caught-increasing-chinese-restrictions?utm_source=rss_feed https://www.scmp.com/news/china/article/1568674/gsk-sleuth-peter-humphrey-caught-increasing-chinese-restrictions?utm_source=rss_feed Thu, 07 Aug 2014 21:00:00 +0000 The only child of corporate investigators Peter Humphrey and Yu Yingzeng has been allowed to visit his parents in their detention centre in Pudong, Shanghai. Harvey Humphrey, 19, told the Sunday Morning Post that he visited his parents - who were arrested for conducting investigations for British drug giant GlaxoSmithKline (GSK) - last Friday afternoon. Harvey said: "It's a bit unusual for the Chinese to do this. I feel something has changed in the Chinese approach to my parents. "The Chinese... https://www.scmp.com/news/china/article/1565243/son-visits-investigator-peter-humphrey-and-his-wife-detention?utm_source=rss_feed https://www.scmp.com/news/china/article/1565243/son-visits-investigator-peter-humphrey-and-his-wife-detention?utm_source=rss_feed Sat, 02 Aug 2014 22:00:45 +0000 Corporate sleuth Peter Humphrey believes he worked for the public good by helping victims of crime, according to a letter seen by the South China Morning Post that he wrote to his son Harvey from prison. On August 8, the Briton and his wife Yu Yingzeng , a Chinese-born US citizen, will be tried at Shanghai No 1 Intermediate People's Court on a charge of illegally obtaining personal information of Chinese citizens. "When I became a business consultant 16 years ago, I concentrated on helping... https://www.scmp.com/news/china/article/1563060/my-work-china-was-public-good-detained-corporate-sleuth-peter-humphrey?utm_source=rss_feed https://www.scmp.com/news/china/article/1563060/my-work-china-was-public-good-detained-corporate-sleuth-peter-humphrey?utm_source=rss_feed Wed, 30 Jul 2014 15:45:45 +0000 Prosecutors have filed charges against British investigator Peter Humphrey and his American wife, Xinhua said on Monday, after the couple were detained last year following work they did for British drugmaker GlaxoSmithKline. In an eight minute news report aired on Monday by state run China Central Television (CCTV), Humphrey said that he and his wife Yu Yingzeng “deeply regret” breaking any Chinese law. He added ChinaWhys would not have worked with GSK if the drugmaker had informed him about the... https://www.scmp.com/article/1553876/prosecutors-charge-gsk-linked-investigators-illegally-obtaining-private-information?utm_source=rss_feed https://www.scmp.com/article/1553876/prosecutors-charge-gsk-linked-investigators-illegally-obtaining-private-information?utm_source=rss_feed Mon, 14 Jul 2014 02:15:23 +0000 The United States has expressed concern after its officials were barred from the Chinese trial of two investigators for British drugmaker GlaxoSmithKline who are accused of illegally buying and selling private information. The arrest last year of American Yu Yingzeng and her British husband Peter Humphrey coincided with Chinese accusations that GSK bribed doctors and officials to use its medications. They face trial on August 7. The US concerns, voiced by its embassy in Beijing, adds a political... https://www.scmp.com/news/china/article/1547058/us-expresses-concern-over-secret-trial-gsk-investigators-china?utm_source=rss_feed https://www.scmp.com/news/china/article/1547058/us-expresses-concern-over-secret-trial-gsk-investigators-china?utm_source=rss_feed Fri, 04 Jul 2014 20:02:32 +0000 British corporate investigator Peter Humphrey and his Chinese-born wife, Yu Yingzeng, will go on trial in Shanghai on July 29. Authorities detained Humphrey and Yu, a US citizen, last July in connection with the pair's investigations on behalf of GlaxoSmithKline (GSK). Recent British newspaper reports have linked their detention to a video of former GSK China head Mark Reilly having sex with a woman, as well as the corruption investigation of Britain's largest drug firm. "We can confirm the... https://www.scmp.com/news/china/article/1543930/briton-peter-humphrey-and-wife-face-trial-glaxosmithkline-saga?utm_source=rss_feed https://www.scmp.com/news/china/article/1543930/briton-peter-humphrey-and-wife-face-trial-glaxosmithkline-saga?utm_source=rss_feed Mon, 30 Jun 2014 19:45:45 +0000 GlaxoSmithKline on Sunday confirmed the existence of an intimate video recording of its former China head, Mark Reilly, which The Sunday Times reported kicked off a bribery investigation that has damaged the drug maker’s business in China. The Sunday Times said the recording was shot without Reilly’s knowledge or consent at his Shanghai flat and showed the Briton, who is separated from his wife, with his Chinese girlfriend. It was not clear who shot the video or with what motivation. The video... https://www.scmp.com/article/1543450/sex-video-new-twist-gsk-china-bribery-scandal?utm_source=rss_feed https://www.scmp.com/article/1543450/sex-video-new-twist-gsk-china-bribery-scandal?utm_source=rss_feed Mon, 30 Jun 2014 03:17:32 +0000 The mainland's crackdown on corruption in the pharmaceutical sector has frightened foreign executives so much that some fear they could be jailed and have asked their lawyers if they should leave the country for six months. Others are thinking of going for good. While the crackdown has been building for a year, police shocked the foreign business community a month ago when they filed corruption charges against Mark Reilly, the former China head of British drugmaker GlaxoSmithKline. The Briton,... https://www.scmp.com/business/china-business/article/1532076/foreign-pharma-executives-mull-china-exit-after-gsk-graft?utm_source=rss_feed https://www.scmp.com/business/china-business/article/1532076/foreign-pharma-executives-mull-china-exit-after-gsk-graft?utm_source=rss_feed Fri, 13 Jun 2014 20:15:30 +0000 The British Serious Fraud Office has opened formal criminal investigation into the commercial practices of GlaxoSmithKline in "numerous" countries. "We are looking at possible patterns across numerous global jurisdictions. Media reports and developments in China have not triggered our announcement. We have been looking at this for some time and it's coincidental that our investigation, which has been in the intelligence phase until now, has now moved to a formal investigation," said a source... https://www.scmp.com/news/world/article/1520218/britains-serious-fraud-office-launches-probe-glaxosmithkline-following?utm_source=rss_feed https://www.scmp.com/news/world/article/1520218/britains-serious-fraud-office-launches-probe-glaxosmithkline-following?utm_source=rss_feed Wed, 28 May 2014 01:30:45 +0000 The Chinese government has publicly accused a British executive of GlaxoSmithKline (GSK) of bribing doctors to use its drugs and then trying to cover up his activities during a subsequent investigation. If convicted, Mark Reilly, the former China head of GSK, could face a prison term - an extremely rare fate for a senior foreign executive on the mainland. Police have completed a 10-month investigation into Britain's largest drug firm, the Ministry of Public Security said on its website... https://www.scmp.com/news/china/article/1511907/chinese-government-accuses-ex-gsk-head-mark-reilly-bribing-doctors?utm_source=rss_feed https://www.scmp.com/news/china/article/1511907/chinese-government-accuses-ex-gsk-head-mark-reilly-bribing-doctors?utm_source=rss_feed Wed, 14 May 2014 04:44:08 +0000 China's health care reforms present opportunities and challenges to foreign health care firms, according to speakers at a recent hearing of the US-China Economic and Security Review Commission, a United States government agency that advises Congress on Sino-US relations. "China's health care reform has generated demand for more and better health care, with opportunities for private and overseas investment," said Huang Yanzhong, senior fellow on global health at the Council on Foreign Relations,... https://www.scmp.com/business/china-business/article/1466828/health-care-reform-china-seen-posing-opportunities-and-risks?utm_source=rss_feed https://www.scmp.com/business/china-business/article/1466828/health-care-reform-china-seen-posing-opportunities-and-risks?utm_source=rss_feed Mon, 07 Apr 2014 01:30:30 +0000 A mainland investigation into bribery allegations against GlaxoSmithKline has prompted the board of the British drugmaker to rein in chief executive Andrew Witty's bonus. Witty's bonus of £1.88 million (HK$24.3 million) was lower than the potential £2.12 million he might have received, Glaxo said yesterday in its annual report. Even so, the bonus was more than double the amount awarded for 2012 after the company won regulatory approval of six products last year. The central government began an... https://www.scmp.com/business/companies/article/1437557/glaxo-cuts-chief-executives-bonus-over-china-bribery-scandal?utm_source=rss_feed https://www.scmp.com/business/companies/article/1437557/glaxo-cuts-chief-executives-bonus-over-china-bribery-scandal?utm_source=rss_feed Fri, 28 Feb 2014 17:14:09 +0000 Britain's Serious Fraud Office plans to prosecute or fine some companies for engaging in bribery overseas, and analysts said some cases might involve mainland China, with GlaxoSmithKline and Rolls-Royce as likely targets. "We have a number of cases in mind but need to look at all the facts," a spokesman with the fraud office told the South China Morning Post. The Bribery Act seeks to punish Britain-linked firms for bribery overseas, and a new policy by the office announced this month could make... https://www.scmp.com/business/companies/article/1432456/gsk-rolls-royce-may-be-british-serious-fraud-offices-hit-list?utm_source=rss_feed https://www.scmp.com/business/companies/article/1432456/gsk-rolls-royce-may-be-british-serious-fraud-offices-hit-list?utm_source=rss_feed Fri, 21 Feb 2014 03:00:45 +0000 The number of employees informing on a company's wrongdoing in Asia, including China, is expected to continue rising with a new policy by the US Securities and Exchange Commission (SEC) to protect the whistle-blowers, analysts say. The global crackdown on corruption and greater financial incentives to report suspected crimes could lead to an increase in cases involving United States and British companies in Asia, according to a report by AlixPartners, an international business advisory... https://www.scmp.com/business/companies/article/1427630/sec-policy-expected-encourage-whistle-blowers-asia?utm_source=rss_feed https://www.scmp.com/business/companies/article/1427630/sec-policy-expected-encourage-whistle-blowers-asia?utm_source=rss_feed Fri, 14 Feb 2014 02:30:45 +0000 GlaxoSmithKline yesterday reported a drop of £125 million (HK$1.57 billion) in mainland sales last year, prompting the British drug giant to talk up its investments in India without mentioning expansion plans in China. Sales of pharmaceuticals and vaccines, which contributed the most to GSK's revenue on the mainland, fell 18 per cent, GSK said in a statement. The decline was accentuated by a 61 per cent plunge in the third quarter. The drop was also partly due to price cuts in its Fenbid drugs... https://www.scmp.com/business/china-business/article/1421705/gsk-sees-sales-drop-ps125m-mainland?utm_source=rss_feed https://www.scmp.com/business/china-business/article/1421705/gsk-sees-sales-drop-ps125m-mainland?utm_source=rss_feed Wed, 05 Feb 2014 20:24:29 +0000 GlaxoSmithKline (GSK) said sales on the mainland, where the company faces a bribery probe, have improved since the third quarter, when revenue plunged 61 per cent year on year. "The trend is definitely looking a bit more positive" since September 30, chief financial officer Simon Dingemans said. "We can see the future opportunities to rebuild the business as and when we get to the other side of the inquiry. We'll be working hard in 2014 to deliver that." Allegations by the central government... https://www.scmp.com/business/china-business/article/1406497/glaxo-says-sales-rise-again-china?utm_source=rss_feed https://www.scmp.com/business/china-business/article/1406497/glaxo-says-sales-rise-again-china?utm_source=rss_feed Wed, 15 Jan 2014 18:37:04 +0000